<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00254436</url>
  </required_header>
  <id_info>
    <org_study_id>ID00-264</org_study_id>
    <nct_id>NCT00254436</nct_id>
  </id_info>
  <brief_title>A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing Preoperative Chemoradiation Followed by Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ortho Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the effectiveness of epoetin alfa on reduction in red blood cell transfusions&#xD;
      in gastric and rectal cancer patients undergoing preoperative chemoradiation therapy followed&#xD;
      by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anemia and fatigue are common problems in gastric and rectal cancer subjects at the&#xD;
      completion of chemoradiation therapy and surgery. Results of several studies in cancer&#xD;
      subjects suggest that treatment with epoetin alfa may be effective in maintaining hemoglobin&#xD;
      levels, thereby reducing fatigue, decreasing transfusion requirement, and potentially&#xD;
      improving quality of life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">October 31, 2001</start_date>
  <completion_date type="Actual">June 29, 2004</completion_date>
  <primary_completion_date type="Actual">June 29, 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients with Reduction in Red Blood Cell Transfusions</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Iron Levels</measure>
    <time_frame>Every 4 weeks</time_frame>
    <description>Iron stores drawn at baseline and every four weeks.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Gastrointestinal Cancer</condition>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Epoetin Alfa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Procrit (epoetin alfa)</intervention_name>
    <description>Weekly dose</description>
    <arm_group_label>Epoetin Alfa</arm_group_label>
    <other_name>Epogen</other_name>
    <other_name>Erythropoietin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female 18 years of age or older&#xD;
&#xD;
          -  Must have a confirmed diagnosis of gastric or rectal cancer for whom the treatment&#xD;
             plan is preoperative chemoradiation followed by surgery&#xD;
&#xD;
          -  Must have a baseline hemoglobin &gt;/= 10 g/dl and &lt; 15 g/dl&#xD;
&#xD;
          -  Must have adequate hematologic function&#xD;
&#xD;
          -  Must have life expectancy of more than 6 months&#xD;
&#xD;
          -  Karnofsky performance status of at least 50%&#xD;
&#xD;
          -  Must have adequate renal function&#xD;
&#xD;
          -  Patients with reproductive potential must use an adequate contraceptive method during&#xD;
             treatment and three months after completing treatment&#xD;
&#xD;
          -  Patients must be able to read, understand, and complete the three Quality of Life&#xD;
             questionnaires in English.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior chemotherapy for patients with rectal cancer&#xD;
&#xD;
          -  Gastric cancer patients who have received more than 2 cycles of chemotherapy&#xD;
&#xD;
          -  Anemia due to factors other than cancer/chemotherapy&#xD;
&#xD;
          -  Patients with prior treatment with epoetin alfa or any investigational forms of&#xD;
             erythropoietin within the previous 6 months&#xD;
&#xD;
          -  Known hypersensitivity to mammalian-cell derived products or to human albumin&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Untreated Central Nervous System metastases&#xD;
&#xD;
          -  Any significant, uncontrolled disease/dysfunction of any of the major organs&#xD;
&#xD;
          -  Uncontrolled hypertension or history of uncontrolled cardiac arrhythmias, pulmonary&#xD;
             embolism, thrombosis&#xD;
&#xD;
          -  New onset or poorly controlled seizures&#xD;
&#xD;
          -  History of active second malignancy&#xD;
&#xD;
          -  Major infection requiring hospitalization and antibiotics or surgery within 14 days of&#xD;
             study entry&#xD;
&#xD;
          -  Blood transfusion within 1 month of study entry&#xD;
&#xD;
          -  Androgen therapy within 2 months of study entry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saroj Vadhan-Raj, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT MDAnderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>November 14, 2005</study_first_submitted>
  <study_first_submitted_qc>November 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2005</study_first_posted>
  <last_update_submitted>October 24, 2018</last_update_submitted>
  <last_update_submitted_qc>October 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epoetin Alfa</keyword>
  <keyword>Epogen</keyword>
  <keyword>Erythropoietin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

